Ocugen, Inc. — Director's Dealing 2016

Dec 19, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HISTOGENICS CORP (HSGX)
CIK: 0001372299
Period of Report: 2016-12-16

Reporting Person: GILL DAVID N (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-12-16	Stock Option (Right to Buy)	$1.58	A	10000	Acquired	2026-12-16	Common Stock (10000)	Direct

Footnotes

F1: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 22, 2016.